ZYME Company Profile and Key Details

Q: Who are the executives of ZYME?

Dr. Ali Tehrani Ph.D.AdvisorDr. Ryan Dercho Ph.D.Senior Director of Corporation AffairsNina Weisser Ph.D.Director of Multispecific Antibody TherapeuticsDr. Paul Moore Ph.D.Chief Scientific OfficerDr. Christopher Astle Ph.D.Senior Vice President & Chief Financial OfficerMr. Neil A. Klompas C.A., CPA, CA, CPAPres & Chief Operating OfficerDr. Neil Josephson M.D.Chief Medical OfficerJack W. SpinksAssociate Director of Investor RelationsMr. Kenneth H. Galbraith C.A.Chief Executive Officer & ChairmanDr. David Poon Ph.D.Vice President of Bus. Devel. and Alliance ManagementDiana PapoveSenior Mang. of Corporation CommunicationsDr. Jeffrey Smith M.D.Senior Vice President of Early-Stage Devel.Mr. Mark HollywoodExecutive Vice President and Head of Technical & Manufacturing OperationsMr. Daniel Dex J.D., Ph.D.Senior Vice President, Corporation Sec. & Gen. CounselMs. Laura O'ConnorExecutive Director & Head of Global HRMs. Bijal Desai M.B.A.Executive Director of Corporation Fin., FP&A & ProcurementMr. Neil A. Klompas C.A., C.P.A., CA, CPAPres & Chief Operating Officer

NASDAQ : ZYME

Zymeworks

$21.94

-0.77-3.39%

At Close 4:00 PM

60.77

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Zymeworks Inc. (ZYME) stock declined over -3.39%, trading at $21.94 on NASDAQ, down from the previous close of $22.71. The stock opened at $22.26, fluctuating between $21.81 and $22.28 in the recent session.

Stock Snapshot

22.71

Prev. Close

1.61B

Market Cap

21.81

Day Low

-16.01

P/E Ratio

-1.37

EPS (TTM)

-1.73

Cash Flow per Share

22.26

Open

73.57M

Number of Shares

22.28

Day High

97.04%

Free Float in %

6.56

Book Value

375.12K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jul 31, 2026	22.75	22.75	21.80	21.94	375.12K
Jul 30, 2026	22.02	23.00	21.90	22.71	402.87K
Jul 29, 2026	22.66	22.96	21.90	22.01	340.48K
Jul 28, 2026	23.20	23.50	22.35	22.61	358.04K
Jul 27, 2026	23.07	23.59	22.99	23.00	259.3K
Jul 24, 2026	23.32	23.69	22.72	22.86	272.38K
Jul 23, 2026	22.98	23.51	22.86	23.12	357.86K
Jul 22, 2026	23.85	24.25	23.28	23.36	388K
Jul 21, 2026	23.81	24.21	23.70	24.05	512.93K
Jul 20, 2026	24.15	24.54	23.73	23.76	437.38K
Jul 17, 2026	24.20	24.59	24.01	24.19	444.69K
Jul 16, 2026	24.75	24.97	24.04	24.19	458.8K
Jul 15, 2026	24.82	24.97	24.24	24.66	326.16K
Jul 14, 2026	24.87	25.22	24.59	24.66	345.95K
Jul 13, 2026	25.79	25.79	24.74	24.94	340.71K
Jul 10, 2026	27.03	27.13	25.36	25.88	482.75K
Jul 09, 2026	26.66	27.41	26.65	27.07	598.1K
Jul 08, 2026	26.62	27.02	25.98	26.65	878.71K
Jul 07, 2026	25.40	26.83	25.31	26.72	771.61K
Jul 06, 2026	26.31	26.36	24.70	25.33	593.3K

Contact Details

Middletown, DE 19709

United States

https://www.zymeworks.com 160 467 81388

About Company

Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.

Stock Peers

ARGX

-18.76-2.15%

argenx SE$853.82 REGN

24.29+3.29%

Regeneron Pharmaceuticals, Inc.$762.63 UTHR

-8.11-1.54%

United Therapeutics Corporation$517.71 VRTX

-4.6-0.95%

Vertex Pharmaceuticals Incorporated$477.10 MDGL

-25.79-5.23%

Madrigal Pharmaceuticals, Inc.$467.32 KRYS

-25.73-7.01%

Krystal Biotech, Inc.$341.12 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ONC

-6.07-1.88%

BeOne Medicines AG$316.01 PRAX

0.08+0.03%

Praxis Precision Medicines, Inc.$307.83 LGND

-8.75-2.95%

Ligand Pharmaceuticals Incorporated$287.54

Company Overview

Zymeworks Inc. (NASDAQ:ZYME) closed at $21.94 USD, losing -$0.77 (-3.39%) from the previous close of $22.71. The stock is currently mid-range between its 52-week high and low $11.51 and $29.75. With a market capitalization of about $1.61 billion, Zymeworks Inc. is classified as a small-cap and shows market-like volatility (beta ~1.13). Key stats such as the average daily volume over the past year has been around 626.13 thousand shares, volume is running light vs its 52-week average. Headquartered in Middletown, DE, Zymeworks Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Kenneth H. Galbraith, the company employs approximately 264 people and listed since April 28, 2017. Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 3.57%, SMA50 -1.42%, SMA200 31.78%). The stock’s 14-day RSI is 54.14 (neutral), while the ATR of 0.96 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -16.43% below its high and over 163.68% above its low. Average 10-day trading volume of 363.00 thousand shares is below the 3-month average of 601.88 thousand, indicating normal recent market interest.

Valuation Metrics

Zymeworks Inc. trades at a P/E ratio of -16.0, slightly below the S&P 500 average, with a price-to-sales ratio of 19.84 and a price-to-book ratio of 10.0 reflecting a rich premium to book value. The P/FCF stands at -20.96, also below market averages.

Dividend & Fair Value

Zymeworks Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$19.25. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Zymeworks Inc. generated EPS of -$0.85 over the past year. Five-year average earnings growth is 15.81%. Wall Street analysts project EPS growth of 51.83% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 7 Strong Buy ratings, 11 Buy ratings, 3 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $58.00 to $15.00. The high target offers 164.36% upside. The low target suggests -31.63% downside. The mean target is $34.38. This offers 56.7% upside. Zymeworks Inc. earnings surprise history is a mixed track record. The quarter that ended May 07, 2026, missed forecasts by 490.0%. The prior quarter beat by 57.14%. Over the last six quarters, Apple has recorded several small beats. These include -3200.0% in March 05, 2025.

Financial & Profitability Overview

Over the trailing twelve months, Zymeworks generated $76.01M in revenue, or $1.10 per share. Gross margin was -88.11%, operating margin -181.62%, and net profit margin -156.13%. Returns are negative, with ROA at -20.43% and ROE at -25.53%.
On valuation metrics, Zymeworks trades at a P/E of -16.00, P/S of 19.84 and P/B of 10.00. The current ratio is 10.82 and quick ratio is 10.82. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -2410.14 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.10, supported by a cash flow-to-debt ratio of -4.40.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Zymeworks posted revenue of $76.01M, down slightly from $412.48M in the prior quarter. Gross profit was - $66.98M (margin -88.11%). Operating income was - $138.05M (margin -181.6%). Net income was- $118.67M (EPS - $1.72).
The company ended the quarter with $374.33M in cash and short-term investments, a total debt of $26.72M, and net debt of - $130.84M. Total assets were $580.88M, with equity of $464.81M. Financials further reflected weakness, with operating cash flow of - $118.30M, free cash flow of - $122.38M, and capital expenditures of - $4.08M.

Price Forecast & Outlook

Our AI price prediction model suggests that Zymeworks Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -9.62%, with price expected at $19.83 by August 13, 2026, within a range of $18.99 to $20.63 3-Month Outlook: Projected rise of 15.41%, reaching $25.32 by October 28, 2026, with a range of $24.39 to $26.33. 1-Year Outlook: Projected gain of 35.1%, with price at $29.64 by July 30, 2027, within a range of $28.61 to $30.80.

Key Takeaways

Zymeworks Inc. (NASDAQ:ZYME) shares are down -10.1% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Zymeworks Inc. trading at a premium to the broader market with a P/E of -16.0. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $26.11, suggesting 19.01% upside. Our AI forecast model points to short-term weakness (-9.62% over two weeks), a medium-term rise (15.41% over three months), and a longer-term gain (35.1% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Zymeworks Inc. (ZYME) stock price?

Zymeworks Inc. (NASDAQ: ZYME) stock price is $21.94 in the last trading session. During the trading session, ZYME stock reached the peak price of $22.28 while $21.81 was the lowest point it dropped to. The percentage change in ZYME stock occurred in the recent session was -3.39% while the dollar amount for the price change in ZYME stock was - $0.77.

ZYME's industry and sector of operation?

The NASDAQ listed ZYME is part of Biotechnology industry that operates in the broader Healthcare sector. Zymeworks Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ZYME?

Dr. Ali Tehrani Ph.D.
Advisor
Dr. Ryan Dercho Ph.D.
Senior Director of Corporation Affairs
Nina Weisser Ph.D.
Director of Multispecific Antibody Therapeutics
Dr. Paul Moore Ph.D.
Chief Scientific Officer
Dr. Christopher Astle Ph.D.
Senior Vice President & Chief Financial Officer
Mr. Neil A. Klompas C.A., CPA, CA, CPA
Pres & Chief Operating Officer
Dr. Neil Josephson M.D.
Chief Medical Officer
Jack W. Spinks
Associate Director of Investor Relations
Mr. Kenneth H. Galbraith C.A.
Chief Executive Officer & Chairman
Dr. David Poon Ph.D.
Vice President of Bus. Devel. and Alliance Management
Diana Papove
Senior Mang. of Corporation Communications
Dr. Jeffrey Smith M.D.
Senior Vice President of Early-Stage Devel.
Mr. Mark Hollywood
Executive Vice President and Head of Technical & Manufacturing Operations
Mr. Daniel Dex J.D., Ph.D.
Senior Vice President, Corporation Sec. & Gen. Counsel
Ms. Laura O'Connor
Executive Director & Head of Global HR
Ms. Bijal Desai M.B.A.
Executive Director of Corporation Fin., FP&A & Procurement
Mr. Neil A. Klompas C.A., C.P.A., CA, CPA
Pres & Chief Operating Officer

How ZYME did perform over past 52-week?

ZYME's closing price is 90.62% higher than its 52-week low of $11.51 where as its distance from 52-week high of $29.75 is -26.25%.

How many employees does ZYME have?

Number of ZYME employees currently stands at 264.

Link for ZYME official website?

Official Website of ZYME is: https://www.zymeworks.com

How do I contact ZYME?

ZYME could be contacted at phone 160 467 81388 and can also be accessed through its website. ZYME operates from 108 Patriot Drive, Middletown, DE 19709, United States.

How many shares of ZYME are traded daily?

ZYME stock volume for the day was 375.12K shares. The average number of ZYME shares traded daily for last 3 months was 626.13K.

What is the market cap of ZYME currently?

The market value of ZYME currently stands at $1.61B with its latest stock price at $21.94 and 73.57M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	264
Beta	1.13
Sales or Revenue	$76.01M
5Y Sales Change%	-0.396%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

ZYME Company Profile and Key Details

Zymeworks

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Earnings & Analyst Outlook

Company Overview

Valuation Metrics

Price Forecast & Outlook

Key Takeaways